Advanced Hepatology & Liver Disease Nursing

Liver Functions & Disease Spectrum

Core Liver Functions

Metabolism

Carbohydrate metabolism: glycogen storage and gluconeogenesis (maintains blood glucose)
Lipid metabolism: fatty acid oxidation, lipoprotein synthesis, cholesterol regulation
Protein metabolism: deamination of amino acids, urea cycle (ammonia detoxification)
Drug and alcohol metabolism via CYP450 enzyme system

Detoxification

Kupffer cells (hepatic macrophages) phagocytose bacteria from portal blood
Bilirubin conjugation: unconjugated (indirect) → conjugated (direct) → excreted in bile
Ammonia converted to urea for renal excretion

Protein Synthesis

Albumin: major plasma oncotic protein; low in chronic liver disease → oedema/ascites
Clotting factors: II, V, VII, IX, X, fibrinogen — liver failure → coagulopathy (raised PT/INR)
Acute phase proteins (CRP, fibrinogen), complement proteins, transport proteins

Bile Production

600–800 mL bile/day: bile salts, cholesterol, bilirubin, phospholipids
Emulsification of dietary fats; fat-soluble vitamin absorption (A, D, E, K)
Cholestasis (bile flow obstruction) → jaundice + steatorrhoea + vitamin K deficiency

Liver Disease Spectrum

Progressive continuum from metabolic dysfunction to end-stage liver disease:

F0
No fibrosis

F1
Mild

F2
Moderate

F3
Advanced

F4
Cirrhosis

Metavir Fibrosis Staging System

MASLD / NAFLD Progression

MASLD (Metabolic-Associated Steatotic Liver Disease) = fatty liver without significant alcohol intake; formerly NAFLD
MASH (Metabolic-Associated Steatohepatitis) = inflammation + hepatocyte injury; formerly NASH
F0–F1 steatosis → MASH → fibrosis progression → cirrhosis → HCC
Risk factors: obesity, T2DM, dyslipidaemia, insulin resistance, hypertension

Hepatocellular Carcinoma (HCC)

Majority arise on background of cirrhosis
Surveillance: USS abdomen + AFP every 6 months in cirrhosis patients
Rising incidence in GCC due to MASLD epidemic and historical HCV burden

Child-Pugh Score

Assesses severity of chronic liver disease; predicts 1-year survival and guides treatment decisions including transplant listing.

Parameter	1 Point	2 Points	3 Points
Bilirubin (μmol/L)	<34	34–51	>51
Albumin (g/L)	>35	28–35	<28
PT prolongation (s)	<4	4–6	>6
Ascites	None	Mild	Moderate–Severe
Encephalopathy	None	Grade 1–2	Grade 3–4

Class A: 5–6 pts (95% survival) Class B: 7–9 pts (75% survival) Class C: 10–15 pts (50% survival)

MELD Score

Model for End-stage Liver Disease — used for transplant prioritisation. Higher score = greater 90-day mortality risk.

MELD = 3.78×ln(Bilirubin mg/dL) + 11.2×ln(INR) + 9.57×ln(Creatinine mg/dL) + 6.43

MELD Score	3-Month Mortality
<10	<5%
10–19	~15–20%
20–29	~35–40%
30–39	~60%
≥40	>75%

💡 MELD ≥15 generally considered threshold for transplant listing. MELD-Na incorporates serum sodium for better mortality prediction.

GCC Context: Liver Disease Epidemiology

MASLD / NAFLD (Most Common)

GCC countries have among the highest global rates of obesity (35–40%) and T2DM (15–20%). Saudi Arabia, UAE, Kuwait prevalence of MASLD estimated at 25–35% of adults. Primary driver of liver disease and HCC in the region.

Viral Hepatitis

HCV: Dramatically declining with Direct-Acting Antivirals (DAAs) achieving SVR >95%. Historical burden from shared needles/blood products. HBV: Endemic in expat workers from South/Southeast Asia. Childhood vaccination programmes now routine across GCC.

Alcohol & Other Causes

Alcohol-related liver disease: Less common in GCC given Islamic prohibition on alcohol. Nonetheless seen in non-Muslim expat population and must not be dismissed. Wilson's disease: Autosomal recessive; copper accumulation; low ceruloplasmin; Kayser-Fleischer rings on slit-lamp; treat with D-penicillamine or trientine.

Cirrhosis & Decompensation

Compensated vs Decompensated Cirrhosis

Compensated Cirrhosis

Portal hypertension established but no overt complications
May be asymptomatic; median survival >10 years
Management: treat underlying cause, surveillance for HCC and varices

Decompensation Events

Ascites (most common — 60% decompensation)
Variceal haemorrhage (GI bleed from portal hypertension)
Hepatic encephalopathy (neuropsychiatric dysfunction)
Jaundice (rising bilirubin, liver synthetic failure)
SBP (spontaneous bacterial peritonitis)

Each decompensation event worsens prognosis; median survival after first decompensation: ~2 years

Ascites

Grading

Grade 1: Detectable only on USS Grade 2: Moderate; distension Grade 3: Tense/large ascites

Management Ladder

Salt restriction: 88 mmol sodium/day (~5g salt) — cornerstone of management
Spironolactone: 100–400 mg/day (aldosterone antagonist — drug of choice); monitor potassium
Furosemide: 40–160 mg/day — add if spironolactone insufficient; maintain 100:40 ratio
Therapeutic paracentesis: for Grade 3/tense ascites — drain up to 5L, more if albumin replacement given
Albumin replacement: 8g per litre drained (for >5L drainage) to prevent post-paracentesis circulatory dysfunction
TIPS: Trans-jugular Intrahepatic Portosystemic Shunt for refractory ascites (non-transplant candidates)

⚠ Refractory ascites: failure to respond to maximum diuretics. Consider TIPS or serial paracentesis. Assess for hepatorenal syndrome.

Spontaneous Bacterial Peritonitis (SBP)

🚨

Diagnostic criterion: Ascitic fluid PMN (polymorphonuclear cells) >250 cells/mm³ — treat empirically without waiting for culture results

Clinical Features

Fever, abdominal pain, tenderness (may be subtle or absent)
Deteriorating encephalopathy or renal function may be the only sign
30-day mortality without treatment: 30–50%

Treatment

Cefotaxime 2g IV TDS for 5 days (first-line); or ceftriaxone 2g OD
Ciprofloxacin: oral step-down if clinically improving after 48h
Albumin: 1.5g/kg day 1, 1g/kg day 3 — reduces risk of hepatorenal syndrome by 66%

Secondary Prophylaxis

Norfloxacin 400mg OD indefinitely after first SBP episode
Co-trimoxazole as alternative where norfloxacin unavailable
Primary prophylaxis: norfloxacin in high-risk cirrhosis (ascitic protein <15g/L + Child C)

Hepatic Encephalopathy (HE)

West Haven Grading

Grade	Clinical Features
Grade I	Mild confusion, sleep disturbance, reduced attention
Grade II	Drowsy but rousable; disorientation; asterixis (liver flap)
Grade III	Marked confusion, somnolent but rousable, gross disorientation
Grade IV	Coma — unresponsive to verbal/painful stimuli

Precipitants (DIGESTED)

Drugs (sedatives, opioids, benzodiazepines)
Infection / SBP
GI bleed (haemoglobin breakdown → ammonia load)
Electrolyte disturbance (hyponatraemia, hypokalaemia)
Surgery / Dehydration / Diuretics
Transjugular portosystemic shunt (TIPS)
Excess dietary protein
Diabetes-related hypoglycaemia

Treatment

Lactulose: 20–30 mL TDS (titrate to 2–3 soft stools/day). Reduces colonic ammonia production and absorption
Rifaximin 550mg BD: non-absorbable antibiotic — second-line/secondary prevention
Identify and treat precipitant; avoid sedatives and nephrotoxins
Protein restriction is NOT recommended — adequate nutrition essential

Hepatorenal Syndrome (HRS)

Functional renal failure in cirrhosis with no intrinsic renal disease — caused by extreme splanchnic vasodilation and renal vasoconstriction.

HRS-AKI (Type 1)

Acute

Creatinine doubles in <2 weeks. Often precipitated by SBP/bleed. Poor prognosis — mortality >50% at 4 weeks without treatment

HRS-CKD (Type 2)

Chronic

Slow decline. Serum Cr >133 μmol/L. Associated with refractory ascites. Median survival 4–6 months

Diagnostic Criteria

Cirrhosis with ascites
Serum creatinine >133 μmol/L or rising by >26.4 μmol/L in 48h
No improvement after 2 days fluid challenge with albumin 1g/kg/day
Absence of shock, nephrotoxic drugs, intrinsic renal disease (proteinuria <500mg/day, no haematuria, normal USS)

Treatment

Terlipressin 1–2mg IV Q4–6H + albumin 20–40g/day — vasopressin analogue; reduces splanchnic vasodilation
Norepinephrine (noradrenaline) infusion as alternative in ICU
Definitive treatment: liver transplantation

Hepatopulmonary & Portopulmonary Syndromes

Hepatopulmonary syndrome: intrapulmonary vascular dilatation → hypoxaemia. Platypnoea (dyspnoea worsened upright). O2 improves with lying. Treated by liver transplant
Portopulmonary hypertension: pulmonary arterial hypertension + portal hypertension. Echo + right heart catheterisation required. Severe form contraindication to transplant

Acute Liver Failure: Recognition & Management

Definition & Classification

Acute liver failure = coagulopathy (INR ≥1.5) AND hepatic encephalopathy developing within 26 weeks of illness onset in a patient without prior liver disease.

Subtype	Timing of Encephalopathy after Jaundice
Hyperacute (fulminant)	<7 days (best prognosis — often paracetamol)
Acute	7–28 days
Subacute	28 days – 26 weeks (worst prognosis for spontaneous recovery)

Aetiology

Cause	Notes
Paracetamol OD	Most common in UK; toxic metabolite NAPQI → hepatocyte necrosis; NAC antidote
Viral hepatitis	HBV (reactivation), HAV, HEV (pregnant women; high risk GCC/South Asia)
Autoimmune hepatitis	Young women; high IgG; ANA/ASMA positive; responds to steroids
Wilson's disease	Young patients; Coombs-negative haemolytic anaemia; low ceruloplasmin; K-F rings
Budd-Chiari syndrome	Hepatic vein thrombosis; painful hepatomegaly; ascites
Drug-induced (DILI)	NSAIDs, isoniazid (TB treatment — GCC relevant), halothane, herbal remedies
Cryptogenic	Unknown cause; 15–20% of cases

King's College Criteria for Transplant Listing

Most widely used prognostic tool in ALF. Poor prognosis indicators justifying emergency transplant listing:

Paracetamol-Induced ALF

🔑

pH <7.30 (after resuscitation)
— OR ALL THREE of: —
• PT >100s (INR >6.5)
• Creatinine >300 μmol/L
• Grade III–IV encephalopathy

Non-Paracetamol ALF

🔑

PT >100s (INR >6.5)
— OR ANY THREE of: —
• Age <10 or >40 years
• Aetiology: non-A, non-B hepatitis or drug-induced
• Jaundice to encephalopathy >7 days
• PT >50s (INR >3.5)
• Bilirubin >300 μmol/L

ICU Nursing Management: Hourly Monitoring

Neurological

Hourly GCS and West Haven HE grade documentation
Grade III–IV: ITU/neurocritical care; raised intracranial pressure (ICP) risk from cerebral oedema
ICP monitoring considered in Grade IV (invasive — risk in coagulopathy)
Head-of-bed elevation 30°; avoid stimulation; treat seizures
Mannitol 0.5–1g/kg bolus for suspected cerebral oedema; hypertonic saline for hypernatraemia target 145–155mmol/L (neuroprotective)

Glucose & Metabolic

Hypoglycaemia risk: impaired glycogen stores + gluconeogenesis
Hourly blood glucose monitoring (encephalopathy can mask hypoglycaemia)
10% glucose infusion continuous + 50% dextrose if hypoglycaemia (<3.5 mmol/L)
Monitor electrolytes: hyponatraemia, hypokalaemia, hypophosphataemia common
Hyponatraemia correction: cautious — rapid correction → central pontine myelinolysis

Coagulopathy

INR is prognostic marker — do NOT correct unless active bleeding or invasive procedure
Vitamin K 10mg IV daily for 3 days
FFP/cryoprecipitate/platelets: only peri-procedure — avoid masking deterioration
Target platelets >50 for invasive procedures
Recheck INR, PT, fibrinogen every 6–8 hours

Paracetamol — NAC Protocol

N-Acetylcysteine (NAC): replenishes glutathione; prevents NAPQI-mediated hepatocyte necrosis
Most effective within 8–10h of ingestion; still beneficial up to 24h
Even beneficial in non-paracetamol ALF (antioxidant, microcirculation)
Standard regimen: 150mg/kg IV over 1h → 50mg/kg over 4h → 100mg/kg over 16h
Anaphylactoid reaction (rash, bronchospasm): reduce rate, antihistamine; re-start at lower rate

Renal & Haemodynamic

Acute kidney injury in ~50% ALF — renal replacement therapy (CVVHDF preferred in haemodynamically unstable)
Avoid nephrotoxic drugs: NSAIDs, aminoglycosides, contrast media
Haemodynamic instability: vasopressors (noradrenaline first-line) in ALF-associated vasodilation
Invasive arterial monitoring; hourly urine output via catheter
Sepsis frequent complication — broad-spectrum antibiotics if suspected

GI / Encephalopathy

Lactulose via NG tube: 20–30 mL Q4H (titrate to 2–3 stools/day)
Lactulose enemas if NG route not available or Grade IV
NG tube early (Grade III+) — aspiration risk; semi-recumbent position
PPI / H2 blocker for stress ulcer prophylaxis
Nasogastric nutrition early (25–30 kcal/kg/day) — high protein requirement

Bridging Therapies & Liver Transplantation

Molecular Adsorbent Recirculating System (MARS)

Albumin dialysis system: removes protein-bound toxins (bilirubin, bile acids, ammonia) not cleared by conventional HD
Reduces bilirubin and ammonia; stabilises haemodynamics
Used as bridge to transplantation or hepatic recovery
Does not replace liver synthetic function (coagulopathy persists)

Liver Transplantation

Emergency transplant for ALF meeting King's College Criteria: 5-year survival ~70%
Without transplant in poor prognosis ALF: mortality >80%
Contraindications: uncontrolled sepsis, multi-organ failure beyond criteria, active substance misuse (recent), irreversible brain damage
Post-transplant: immunosuppression (tacrolimus, MMF, prednisolone), rejection monitoring, infection prophylaxis

Liver Investigations & Monitoring

Liver Function Tests (LFTs) Interpretation

Test	Normal	Significance	Clinical Pattern
ALT (alanine aminotransferase)	7–56 U/L	Hepatocellular damage — most specific for liver injury	Elevated in hepatitis, MASLD, drug injury
AST (aspartate aminotransferase)	10–40 U/L	Less specific; also elevated in cardiac/muscle disease	AST:ALT >2:1 suggests alcoholic liver disease
ALP (alkaline phosphatase)	44–147 U/L	Cholestasis, bone disease, infiltrative liver disease	Elevated with GGT = hepatic cholestasis
GGT (gamma-glutamyl transferase)	<55 U/L	Alcohol, cholestasis, enzyme induction (drugs)	Elevated GGT with normal ALP = alcohol marker
Bilirubin (total)	<21 μmol/L	Jaundice threshold: >35 μmol/L. Direct/indirect ratio determines type	Direct dominant = cholestatic/conjugated; indirect = haemolysis/pre-hepatic
Albumin	35–50 g/L	Hepatic synthetic function (half-life ~20 days)	Low in chronic liver disease, malnutrition, nephrotic syndrome
PT / INR	11–13.5s / <1.2	Most sensitive synthetic function marker (short half-life)	Raised in acute hepatitis, cirrhosis, vitamin K deficiency

💡 AST:ALT ratio: Ratio >2:1 in alcoholic hepatitis (mitochondrial damage preferentially raises AST). In viral hepatitis/MASLD: ALT usually predominates.

Hepatitis Serology

Hepatitis B Markers

Marker	Meaning
HBsAg	Surface antigen — presence = current infection or carrier
Anti-HBs	Surface antibody — immunity (vaccination or resolved infection)
Anti-HBc IgM	Core antibody IgM = acute/recent HBV infection
Anti-HBc IgG	Past exposure (with or without immunity)
HBeAg	e-antigen — marker of active viral replication and high infectivity
Anti-HBe	Seroconversion — lower infectivity (unless pre-core mutant)
HBV DNA	Viral load — guides treatment threshold; monitors response

Hepatitis C Markers

Marker	Meaning
Anti-HCV	Antibody — past or current infection; does NOT indicate immunity
HCV RNA (PCR)	Confirms active viraemia; quantitative = viral load for monitoring
HCV genotype	1–6; guides DAA choice (pan-genotypic DAAs now cover all)
SVR (12)	Sustained Virological Response at 12 weeks = cure (>95% with DAAs)

Non-Invasive Fibrosis Assessment

FIB-4 Score

FIB-4 = (Age × AST) / (Platelet count × √ALT)

<1.30: Low risk (F0–F1) 1.30–2.67: Indeterminate >2.67: High risk (F3–F4)

APRI Score

APRI = (AST / Upper Limit Normal) / Platelet × 100

<0.5: Unlikely significant fibrosis >1.5: Likely cirrhosis

FibroScan (Transient Elastography)

Measures liver stiffness in kPa. Non-invasive, reproducible, point-of-care.

Stiffness (kPa)	Metavir Stage
<7.0	F0–F1 (minimal/no fibrosis)
7.0–9.5	F2 (significant fibrosis)
9.5–12.5	F3 (advanced fibrosis)
>12.5	F4 (cirrhosis)

⚠ FibroScan overestimates stiffness in: acute hepatitis (inflammation), congestive cardiac failure, post-prandial state, high BMI. Avoid within 2h of meal.

Portal Hypertension Diagnosis

Ultrasound Doppler

Portal vein diameter >13 mm: suggests portal hypertension
Splenomegaly (>12 cm long axis): splenic congestion from portal hypertension
Varices visualised: gastric, splenic; ascites detectable from 100 mL
Hepatic vein Doppler: monophasic waveform in cirrhosis (normally triphasic)
Porto-systemic collaterals: spleno-renal, para-umbilical vein (caput medusae)

HVPG (Hepatic Venous Pressure Gradient)

Gold standard for portal hypertension measurement; difference between wedged and free hepatic venous pressures.

<6 mmHg: Normal 6–10 mmHg: Portal hypertension (no clinical consequences) >10 mmHg: Clinically significant (ascites/varices risk) >12 mmHg: Variceal bleeding risk

Liver Biopsy

Indications

Diagnosis of autoimmune hepatitis, DILI, alcoholic hepatitis, Wilson's disease
Fibrosis staging when non-invasive tests are inconclusive
Pre-treatment assessment (e.g., before immunosuppression)

Approaches

Route	Indication	Notes
Percutaneous (USS-guided)	Standard approach	Requires INR <1.5, platelets >50
Trans-jugular (TJLB)	Coagulopathy, ascites, obesity	Safer — bleeding contained within hepatic vein
Laparoscopic	Focal lesion targeting	Direct visualisation; under GA

Post-Biopsy Nursing Care

Bedrest minimum 4 hours (right lateral position — tamponades puncture site)
Haemorrhage is most common complication — monitor pulse, BP, pain every 15 min × 1h, then 30 min × 4h
Pain at biopsy site ± right shoulder tip pain (referred diaphragmatic irritation from blood)
Haemobilia (delayed — biliary tract bleeding): jaundice + RUQ pain + GI bleed triad
Pneumothorax risk: monitor SpO2 and respiratory symptoms
Haemodynamic instability → urgent USS + surgical review
Outpatient biopsy: minimum 6h observation; responsible adult escort

Oesophageal Varices & Haemorrhage Management

Acute Variceal Haemorrhage: Resuscitation Protocol

Immediate Actions (0–30 minutes)

Airway: intubate Grade III–IV encephalopathy before endoscopy (aspiration risk)
Two large-bore (14–16G) IV cannulae; send FBC, U&E, LFTs, coagulation, crossmatch 6 units
Resuscitate with crystalloid until blood available — avoid excessive saline
Transfuse: target Hb 70–80 g/L (over-transfusion elevates portal pressure → re-bleeding)
Terlipressin 2mg IV QDS (4–6 hourly) — reduces portal pressure; continue up to 5 days
Ceftriaxone 1g IV OD (prophylactic antibiotics — reduces mortality by 10%)
NGT: consider after intubation for active encephalopathy
Urgent endoscopy within 12 hours of presentation

Drug Therapy

Terlipressin (Vasopressin Analogue)

Dose: 2mg IV every 4–6 hours; reduce to 1mg QDS after haemostasis
Duration: up to 5 days after haemostasis
Mechanism: splanchnic vasoconstriction → reduces portal blood flow and pressure
Contraindications: known ischaemic heart disease, peripheral vascular disease, severe asthma, pregnancy
Adverse: bradycardia, peripheral ischaemia, hyponatraemia — monitor ECG and limbs

💊

Antibiotic prophylaxis (ceftriaxone 1g/day IV × 7 days) reduces infection and re-bleeding rates, and independently reduces 30-day mortality. Do NOT omit.

Endoscopic Treatment

Endoscopic Variceal Ligation (EVL / Band Ligation)

First-line endoscopic treatment for oesophageal varices
Rubber bands applied at endoscopy to ligate varices; strangulate over days
Post-EVL: risk of banding ulcers at 7–14 days — significant re-bleed risk
Repeat every 4 weeks until obliteration; then surveillance every 3–6 months

Endoscopic Sclerotherapy

Injection of sclerosing agent (ethanolamine oleate, sodium tetradecyl sulphate) into varix
More complications than EVL (ulceration, stricture) — now mostly used when EVL not technically possible
Still used for gastric varices (Histoacryl glue injection)

✓ Active variceal bleeding: endoscopy within 12 hours. After haemostasis, second-look endoscopy at 48–72 hours recommended.

Balloon Tamponade: Sengstaken-Blakemore Tube

Temporary mechanical haemostasis when endoscopy unavailable or fails. Bridge to definitive therapy only — maximum 24h inflation.

Nursing Management

Patient should be intubated before insertion (airway protection essential)
Nurse semi-recumbent at 30–45° — reduces aspiration risk
Confirm position by CXR before inflating oesophageal balloon
Inflate gastric balloon first with 250–300 mL air; confirm with CXR; apply traction
Oesophageal balloon: inflate to 25–45 mmHg if gastric tamponade insufficient; check pressure every 3h
Aspirate oesophageal lumen port hourly — pooled secretions increase aspiration risk
Deflate oesophageal balloon for 30 min every 8h (prevent mucosal necrosis)
Mark tube at lip/teeth — prevent migration (upward migration = oesophageal rupture risk)
Scissors at bedside — emergency deflation if airway obstructed
Remove when definitive therapy arranged (max 24h)

🚨 Oesophageal rupture/perforation is a catastrophic complication. Any sudden clinical deterioration — deflate immediately.

TIPS (Trans-jugular Intrahepatic Portosystemic Shunt)

Indications

Refractory variceal haemorrhage (failure of 2 endoscopic treatments)
Refractory ascites (non-transplant candidates)
Early TIPS (<72h) in Child-Pugh B active bleeding or Child-Pugh C cirrhosis — improves survival
Budd-Chiari syndrome

Procedure

Radiological procedure: trans-jugular access → right hepatic vein → needle through liver parenchyma → portal vein → metal stent placed to create low-resistance porto-systemic shunt
Immediately reduces portal pressure; highly effective at stopping bleeding

Post-TIPS Nursing Care

Hepatic encephalopathy risk increases significantly post-TIPS (shunting of ammonia-rich portal blood past liver)
Neurological observations every 4h; lactulose prophylaxis; rifaximin for recurrent HE
Stent stenosis/occlusion: USS Doppler at 1 month then 6-monthly — assess flow velocity
Monitor for haemolysis (PTFE-covered stents have reduced this complication)
Worsening liver function possible — monitor LFTs and INR

Primary & Secondary Prevention

Primary Prevention (Never Bled)

Non-selective beta-blockers: propranolol 40mg BD (titrate to 25% reduction in resting heart rate) OR carvedilol 6.25–12.5mg OD — for medium–large varices on endoscopy
EVL: alternative to beta-blockers; for high-risk varices (red wale signs, large size)
Beta-blockers AND EVL: not proven superior to either alone in primary prevention
Endoscopic variceal screening: at cirrhosis diagnosis; if no varices — repeat every 2–3 years

Secondary Prevention (After Bleeding)

Combination therapy: non-selective beta-blocker + EVL — superior to either alone
Re-bleeding risk without secondary prophylaxis: 60% within 1 year
Consider TIPS for patients who re-bleed on combination therapy
Beta-blockers: haemodynamic contraindications — heart failure (EF <40%), bronchospasm/COPD, significant hypotension, peripheral vascular disease

✓ Carvedilol (alpha+beta-blocker) reduces portal pressure more effectively than propranolol; may be preferred in patients with inadequate HR response to propranolol. Starting dose: 6.25mg OD.

GCC Context & Exam Preparation

MASLD Epidemic in the GCC

The GCC region has among the highest global prevalence rates of obesity (Saudi Arabia 35%, Kuwait 40%), T2DM (Saudi Arabia 18%), and metabolic syndrome. This drives an epidemic of MASLD and MASH, making it the leading cause of chronic liver disease across the region — surpassing viral hepatitis.

Key risk factors in GCC: sedentary lifestyle, high-calorie diets, rapid urbanisation, and genetic predisposition (PNPLA3 gene variants prevalent in Arab populations). Nursing role: metabolic risk screening, lifestyle counselling, and long-term hepatology follow-up coordination.

Viral Hepatitis in the GCC

HCV: Historical burden from contaminated blood products and sharps. Pan-genotypic DAAs (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) now achieve SVR >95% in 8–12 weeks. Saudi Arabia, UAE, Egypt all have national HCV elimination programmes. Nurses must educate on treatment adherence and post-SVR HCC surveillance in cirrhotics.

HBV: Imported disease — high prevalence in expat South/Southeast Asian workers. Universal vaccination programmes now running. Perinatal transmission prevented by HBIg + vaccine within 12h of birth. Tenofovir/entecavir for treatment.

Liver Transplant Programmes

King Faisal Specialist Hospital & Research Centre (KFSH&RC), Riyadh: Largest and oldest liver transplant programme in the Middle East. Established 1990. Performs both deceased and living donor transplants. Internationally accredited.

King Hamad University Hospital, Bahrain: Regional centre providing transplantation services to Bahraini nationals and regional referrals.

UAE (Abu Dhabi & Dubai), Kuwait, Qatar: Active deceased donor programmes; regional referral network for complex cases.

Living Donor Liver Transplant (LDLT)

LDLT is proportionally more common in GCC than Western countries. Driving factors include: shortage of deceased organ donors (lower consent rates), strong family-centred culture, and Islamic scholarly consensus (fatwa) permitting living organ donation as an act of benevolence (sadaqah) with informed consent and no commercialisation.

Right lobe LDLT is the standard adult-to-adult procedure. Donor risk: 0.2–0.5% mortality, 30–40% minor morbidity. Rigorous donor evaluation (hepatic volumetry, biopsy, psychology assessment) essential. Nursing role: donor and recipient preoperative education, psychological support.

DHA / DOH / SCFHS Exam Focus Areas

Liver Failure Recognition

Coagulopathy (raised INR) + encephalopathy = acute liver failure definition
Jaundice + confusion + coagulopathy in a young patient — think Wilson's, autoimmune, paracetamol
Paracetamol history — check time of ingestion; plot on Rumack-Matthew nomogram
King's College Criteria: pH <7.30 OR all three (PT >100s, Cr >300, Grade III–IV HE) for paracetamol ALF
Cerebral oedema: hypertension + bradycardia + abnormal breathing = Cushing's triad

Variceal Haemorrhage Emergency

Haematemesis/melaena in cirrhosis = presumed variceal until proven otherwise
Major haemorrhage protocol: 2 large bore IV access, crossmatch 6 units, activate team
Terlipressin 2mg QDS + ceftriaxone 1g OD = two key immediate drugs
Target Hb 70–80 g/L — do NOT over-transfuse
Endoscopy within 12 hours of presentation for band ligation
Sengstaken-Blakemore tube = bridge only; always intubate first

Key Drug Knowledge

Spironolactone (aldosterone antagonist) — first-line for ascites; monitor K+
Lactulose — target 2–3 soft stools/day for encephalopathy
Rifaximin — non-absorbable antibiotic; secondary prevention of HE
Norfloxacin — SBP prophylaxis after first episode
Terlipressin — variceal haemorrhage; HRS-AKI; CI in IHD
N-acetylcysteine — paracetamol overdose; anaphylactoid reactions possible
Propranolol/carvedilol — variceal primary and secondary prophylaxis

Interactive Child-Pugh Score Calculator

Select values for each parameter to calculate the Child-Pugh class and survival estimate.

Patient Parameters

Bilirubin (μmol/L)

Albumin (g/L)

PT Prolongation (seconds)

Ascites

Hepatic Encephalopathy

Practice MCQs (10 Questions)

Click an option to reveal the correct answer and explanation.

Q1. A patient with known cirrhosis presents with confusion, asterixis and is passing 4 loose stools daily on lactulose. Which medication should be added to improve long-term prevention of hepatic encephalopathy recurrence?

A. Metronidazole
B. Rifaximin
C. Neomycin
D. Norfloxacin

Q2. You perform diagnostic paracentesis on a patient with decompensated cirrhosis. The ascitic fluid PMN count is 380 cells/mm³. What is the diagnosis and initial treatment of choice?

A. Secondary bacterial peritonitis — surgery
B. SBP — cefotaxime + albumin
C. SBP — oral ciprofloxacin only
D. Tense ascites — therapeutic paracentesis

Q3. A 28-year-old presents with acute liver failure (INR 7.2, Grade III encephalopathy, creatinine 320 μmol/L). Paracetamol was taken 36 hours ago. Which statement is correct regarding N-acetylcysteine (NAC)?

A. NAC should not be given as it is only effective within 8 hours
B. NAC should be given orally
C. IV NAC should be administered — still beneficial beyond 24 hours
D. NAC is contraindicated given the coagulopathy

Q4. A cirrhotic patient undergoes therapeutic paracentesis draining 7 litres of ascitic fluid. What is the correct albumin replacement dose?

A. 4g albumin per litre drained
B. 8g albumin per litre drained (= 56g total)
C. 20g albumin per litre drained
D. Albumin not required if drain is <10 litres

Q5. A patient on a Sengstaken-Blakemore tube suddenly becomes acutely distressed and hypoxic. What is the priority nursing action?

A. Call for the senior nurse immediately
B. Reposition the patient to the left lateral position
C. Cut and remove the tube immediately with scissors
D. Increase the oesophageal balloon pressure

Q6. Which of the following is the MOST COMMON cause of liver disease in GCC countries?

A. Alcohol-related liver disease
B. Hepatitis C (HCV)
C. MASLD / NAFLD (metabolic-associated steatotic liver disease)
D. Hepatitis B (HBV)

Q7. A patient with cirrhosis is prescribed spironolactone 200mg OD and furosemide 80mg OD for ascites. Their latest potassium is 5.9 mmol/L. What is the most appropriate action?

A. Increase spironolactone to 400mg OD
B. Add potassium supplementation
C. Withhold/reduce spironolactone; consider increasing furosemide
D. Withhold all diuretics and give IV fluids

Q8. During post-liver biopsy monitoring, a patient develops right shoulder tip pain, pulse 110 bpm, BP 95/60 mmHg. What is the most likely complication and priority action?

A. Pneumothorax — high-flow oxygen
B. Haemorrhage — urgent USS, IV access, crossmatch
C. Vagal reaction — lie patient flat
D. Haemobilia — endoscopy

Q9. A Child-Pugh score is calculated: bilirubin 45 μmol/L, albumin 31 g/L, PT prolongation 5 seconds, mild ascites, grade I encephalopathy. What is the Child-Pugh class?

A. Child-Pugh Class A
B. Child-Pugh Class B
C. Child-Pugh Class C
D. Child-Pugh Class D

Q10. Which blood transfusion target is recommended during active variceal haemorrhage resuscitation, and why?

A. Haemoglobin >100 g/L — restore normal haematocrit
B. Haemoglobin 70–80 g/L — restrictive strategy reduces re-bleeding
C. No transfusion until Hb <50 g/L
D. Haemoglobin 90–100 g/L — same as standard GI bleed